AmirAli Talasaz is co-founder and co-CEO of Guardant Health, a leading precision oncology company. Talasaz is an entrepreneur in the rare genomics and clinical diagnostics fields. Prior to co-founding Guardant Health, he was senior director of diagnostics research at Illumina, where he led efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different genomic technologies suitable for clinical applications. Before Illumina, Talasaz founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by Illumina in 2009. During his academic years, Talasaz led the Technology Development Group at Stanford Genome Technology Center. (Guardant Health is a 2023 Festival Underwriter)
Previously
Remarkable screening and diagnostic tools are being developed so that disease can be identified in its earliest stages, when it is most treatable, and disease subtypes can be...